Rainmed Medical (HKSE:02297) Research & Development: HK$15.14 Mil (TTM As of Dec. 2025)


HKSE:02297 Rainmed Medical Ltd HKSE:02297
49 GF Score
Price HK$0.22
GF Value HK$0.08
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Rainmed Medical Research & Development?

Rainmed Medical HKSE:02297 49 Research & Development is HK$15.14 Mil as of Dec. 2025. GuruFocus rates HKSE:02297 with a GF Score™ of 49/100 and a GF Value™ of HK$0.08 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Rainmed Medical's Research & Development for the six months ended in Dec. 2025 was HK$8.18 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was HK$15.14 Mil.

Rainmed Medical  (HKSE:02297) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Rainmed Medical Research & Development Related Terms

Rainmed Medical Research & Development Historical Data

* Premium members only.

The historical data trend for Rainmed Medical's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rainmed Medical Research & Development Chart

Rainmed Medical Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 33.02 49.33 45.20 37.84 15.21

Rainmed Medical Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 20.47 19.88 18.12 6.95 8.18
HKSE:02297
49GF Score
Rainmed Medical Ltd HKSE:02297
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rainmed Medical Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$15.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$15.14 Mil mean?
Rainmed Medical (HKSE:02297) has a Research & Development of HK$15.14 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Rainmed Medical and its competitors.
Is Rainmed Medical's Research & Development too high?
Rainmed Medical's current Research & Development is HK$15.14 Mil. Overall, Rainmed Medical has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Rainmed Medical's Research & Development compare to ABT and SYK?
Rainmed Medical's Research & Development of HK$15.14 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Rainmed Medical and its competitors. Rainmed Medical's current Research & Development is HK$15.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rainmed Medical stock overvalued right now?
Based on GuruFocus' analysis, Rainmed Medical (HKSE:02297) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.08, compared to a current price of HK$0.22 — trading 175% above its estimated fair value. The current Research & Development is HK$15.14 Mil. Rainmed Medical's overall GF Score™ is 49/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Rainmed Medical (HKSE:02297), the current Research & Development is HK$15.14 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rainmed Medical (HKSE:02297) Overvalued in 2026?

Based on GuruFocus' analysis, Rainmed Medical stock appears to be overvalued. The current stock price of HK$0.22 is trading 175% above its estimated GF Value™ of HK$0.08. GuruFocus considers Rainmed Medical to be Significantly Overvalued.

Key valuation signals for HKSE:02297:

  • Research & Development: HK$15.14 Mil
  • GF Value™: HK$0.08 vs. price of HK$0.22 (175% above fair value)
  • GF Score™: 49/100 with 9 warning signs

No single metric tells the full story. See the HKSE:02297 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rainmed Medical Business Description

Address No. 99, Jinji Lake Avenue, Room NW-05-502, Building 31, Nanopolis Suzhou, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215000
Rainmed Medical Ltd is focused on the design, development, and commercialization of coronary angiography-derived fractional flow reserve systems and coronary angiography-derived index of microcirculatory resistance systems. The company's core products, the caFFR system and the caIMR system, are medical devices used to evaluate the severity of myocardial ischemia arising from coronary artery stenosis and microvascular dysfunction, which are the underlying causes of coronary artery diseases (CAD). It operates in China and Other countries.
49GF Score

Get the complete analysis for HKSE:02297

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.22
Price
HK$0.08
GF Value